 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rezolute, Inc. (NASDAQ:RZLT  Get Free Report) insider Brian Kenneth Roberts acquired 10,000 shares of the stock in a transaction on Thursday, March 14th. The shares were purchased at an...

Rezolute, Inc. (NASDAQ:RZLT) Insider Brian Kenneth Roberts Buys 10,000 Shares

Rezolute (NASDAQ:RZLT  Get Free Report) and SCYNEXIS (NASDAQ:SCYX  Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two...

Reviewing Rezolute (NASDAQ:RZLT) & SCYNEXIS (NASDAQ:SCYX)

Rezolute, Inc. (NASDAQ:RZLT  Get Free Report) CFO Daron Evans purchased 50,000 shares of the stock in a transaction on Friday, March 8th. The shares were purchased at an average cost of $1.93...

Rezolute, Inc. (NASDAQ:RZLT) CFO Daron Evans Acquires 50,000 Shares

Rezolute (NASDAQ:RZLT  Get Free Report)s stock had its buy rating reaffirmed by HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a...

Rezolute (NASDAQ:RZLT) Stock Rating Reaffirmed by HC Wainwright

Rezolute, Inc. (NASDAQ:RZLT  Get Free Report) CFO Daron Evans purchased 50,000 shares of the companys stock in a transaction that occurred on Friday, March 8th. The shares were...

Daron Evans Acquires 50,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism)
 Effects of RZ358 on Ligand-Induced...

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

HC Wainwright reaffirmed their buy rating on shares of Rezolute (NASDAQ:RZLT  Free Report) in a report released on Wednesday, Benzinga reports. HC Wainwright currently has a $14.00 price...

Rezolute (NASDAQ:RZLT  Get Free Report)s stock had its buy rating restated by HC Wainwright in a report issued on Wednesday, Benzinga reports. They presently have a $14.00...

Rezolute (NASDAQ:RZLT) Receives "Buy" Rating from HC Wainwright

Key Insights Rezolute's estimated fair value is US$0.87 based on 2 Stage Free Cash Flow to Equity Rezolute's US$1.14...

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for...

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperinsulinism, AB101-Phase 1, a once-weekly injectable basal insulin, and RZ402, which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.

Volume (M)	782,714.00
52-Wk High	$3.49
52-Wk Low	$0.72

RZLT Rezolute Inc

About

Feed

News

Earnings

Fundamentals